International Migrants and AMR

  29 November 2022

Migrants and refugees across the world often face poorer health outcomes as a result of social and systemic discrimination, language and cultural barriers, and limited or lack of access to health services.* For this vulnerable population, unsafe or inadequate housing during migration, and exposure to pathogens during traveling increase the risk of acquiring communicable diseases (Vignier 2018), and this is compounded by the higher risk of contracting drug-resistant infections, often called superbugs. Drug resistance or antimicrobial resistance (AMR) develops when germs mutate and change over time and become resistant to the medicines that are used to treat them. Drug resistance complicates treatment and increases the chances of disease transmission and spread. AMR can develop or worsen as a result of delayed or limited medical care and heightened rates of infection. In this brief commentary, we explore recent literature and research on how migration and related factors can increase migrants’ vulnerability to drug-resistant infections.

 

Further reading: One Health Trust
Author(s): Aditi Satyavrath, Samantha Serrano
Effective Surveillance  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Evotec

JSS University

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS





Technology Database

Display your AMR Technology, Product and Service

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!